+86 400-821-9890

Dr. Milind Javle

Dr. Javle is the current chair of the International Cholangiocarcinoma Research Network (ICRN). He received his medical degree in Grant Medical College, India, completed his fellowship and residency at Roswell Park Cancer Center, Buffalo, NY.
He is a Professor of Gastrointestinal (GI) Medical Oncology at the MD Anderson Cancer Center in Houston, TX. He has served in the past as Assistant Professor of Medical Oncology at Roswell Park Cancer Institute and has been a faculty member at MD Anderson Cancer Center since 2007, in the GI Medical Oncology Division, with research interests in pancreatic and biliary cancers. His research interests include identification of molecular subtypes of pancreatic and biliary cancers and development of novel therapeutics against these cancers. He has over 150 peer reviewed papers, national and international, philanthropic and pharmaceutical grants. He is the Chair of Southwest Oncology Group Hepatobiliary Committee and member of the NCI task force on Hepatobiliary Cancers.

Dr. Mitesh Borad

Dr. Mitesh J. Borad is an Assistant Professor of Medicine and Director of Phase I Drug Development at Mayo Clinic in Arizona. He obtained his internal medical training at Cedars-Sinai Medical Center and completed his medical oncology fellowship at Tulane University School of Medicine. Prior to joining Mayo Clinic, he spent 3 years at the Translational Genomics Research Institute as a Genomics Medicine Scholar. He has been serving on the NCI Hepatobiliary Task Force since 2011. His research and clinical interests are in development of novel treatments for patients with biliary and liver cancers. His team has been engaged in whole genome analysis efforts in cholangiocarcinoma with focus on discovery of novel drug targets and their subsequent implementation in the clinic with the long-range goal of providing precision medicine to patients with cholangiocarcinoma.

Dr. Funda Meric-Bernstam

Funda Meric-Bernstam, MD, is Chair of the Department of Investigational Cancer Therapeutics, Medical Director of the Institute for Personalized Cancer Therapy (IPCT), and a Professor in the Divisions of Cancer Medicine and Surgery at MD Anderson Cancer Center. Her basic and translational research focuses on molecular therapeutics, predominantly on PI3K/Akt/mTOR signaling, to delineate the mechanism of action agents targeting this pathway and the molecular alterations to identify patients who will benefit from each agent, and combination therapies. Her research seeks to identify molecular markers for predisposition testing, disease screening and prognostic assessment, as well as markers to predict and monitor drug response. As Medical Director of the IPCT, she leads large genomic testing efforts; helped build a framework to assess actionability of genomic alterations; established a Precision Oncology Decision Support Team that provides input for actionability; launched the personalizedcancertherapy.org website, which provides information on therapeutic relevance of specific genes/variants; created databases and alert systems to facilitate accrual to genotype-selected trials; and monitors trial enrollment after genomic testing. She leads and participates in investigator-initiated trials, cooperative group trials, and industry sponsored trials, ranging from window-of-opportunity trials, neoadjuvant therapy trials, and Phase I/II trials in advanced cancers, as well as trials of new surgical techniques, imaging devices, and molecular diagnostics. She joined MD Anderson as an assistant professor in 2001 after completing her research fellowship here. She completed her residency at the University of Michigan Medical Center and a postdoctoral fellowship at the National Institutes of Health.

Dr. Flavio Rocha

Dr. Rocha is a staff surgeon at Virginia Mason Medical Center. He also holds appointments as a Clinical Assistant Professor of Surgery at the University of Washington and an Affiliate Investigator at BRI. He attended the Pritzker School of Medicine at the University of Chicago followed by general surgery residency at the Brigham and Women’s Hospital and a postdoctoral research fellowship in tissue engineering at Harvard Medical School. After residency, he completed a surgical oncology and hepatopancreatobiliary surgery fellowship at Memorial Sloan-Kettering Cancer Center. His clinical practice involves all aspects of benign and malignant disease of the liver, bile ducts and pancreas. Dr. Rocha serves as the Director of Research for the Digestive Disease Institute and Associate Medical Director of the Cancer Institute. He is a member of several cancer cooperative groups including the Alliance for Clinical Trials in Oncology and the Eastern Cooperative Group and serves on the Pancreas Task Force at the National Cancer Institute. He is also on the executive committee of the International Cholangiocarcinoma Research Network. Dr. Rocha's research focuses on clinical and translational studies in pancreaticobiliary cancer. This includes biomarker discovery and validation in cholangiocarcinoma and outcomes research following chemotherapy and surgical resection of pancreas cancer. He also performs health services research using large population-based repositories such as the National Cancer Database. Lastly, he serves as a co-investigator for several clinical trials in hepatopancreatobiliary cancers and the PI for the BRITE Tumor Registry.

Dr. Charles Rosen

Professor of Surgery, Mayo Clinic College of Medicine Director
William J. von Liebig Center for Transplantation and Clinical Regeneration Medical Director
Department of Contracting and Payer Relations Mayo Clinic

Charles Rosen, M.D. is Director of the William J. von Liebig Center for Transplantation and Clinic Regeneration at Mayo Clinic Rochester. He is the Medical Director for Contracting and Payer Relations for Mayo Clinic. He served as Chair of the Division of Transplantation Surgery (1999 – 2017) and Surgical Director of Liver Transplantation at Mayo Clinic (1998 – 2008). He has also served as President of the Board of Directors and Medical Director for LifeSource (2007 – 2008), the organ procurement organization serving Minnesota, North and South Dakota. He served as faculty co-chair for the HRSA Transplant Center Growth and Management Collaborative 2007 – 2008 and was a member of the faculty of the HRSA Organ Donation and Transplantation Collaborative 2005 – 2006. He graduated from Phillips Exeter Academy in 1977 and received his bachelor’s degree in biochemistry from Harvard University in 1980. He received his medical degree from Mayo Medical School in 1984. He completed a residency in general surgery in 1989 and a fellowship in transplantation surgery in 1991 at the Mayo Graduate School of Medicine. Prior positions include Surgical Director of Liver Transplantation at Saint Luke’s Hospital of Kansas City (1991 - 1993), Senior Associate Consultant in Transplantation Surgery at Mayo Clinic Rochester (1993 – 1994), and Associate Professor of Surgery in the Division of Transplantation Surgery at the University of Florida (1995 – 1998). Academic and clinical areas of interest include liver transplantation, living donor liver transplantation, transplantation for cholangiocarcinoma and other hepatobiliary tumors, and deceased donor organ utilization and procurement.

Dr. Rachna Shroff

Dr. Shroff is an Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. She is interested in developing personalized, targeted therapy for biliary and pancreatic malignancies, molecular markers and biomarker development, novel pathways and therapies in gastrointestinal cancers.

Dr. Jeffrey Lee

Jeffrey Lee, MD, MPH, FASGE, FACG AGAF
Jeffrey Lee, MD, is currently a Professor of Medicine in the Department of Gastroenterology of the M D Anderson Cancer Center in Houston, Texas. He also serves as the Director of Advanced Endoscopy Fellowship and is the President-elect for Texas Society of Gastroenterology and Endoscopy. Dr. Lee completed a residency in Internal Medicine and a fellowship in Gastroenterology at the University Of California, Davis. Subsequently he completed a fellowship in Advanced Therapeutic Endoscopy at Harvard Medical School. Dr. Lee’s main academic interests include diagnosing and staging of various gastrointestinal malignancies, gallbladder cancer, biliary and pancreatic diseases, and state-of-the art advances in the use of endoscopy as a therapeutic tool.
He served as the Chair of the ERCP Committee in the American Society for Gastrointestinal Endoscopy and on the International Relations Committee in the American College of Gastroenterology and Annual Scientific Program Committee of Digestive Disease Week. He currently serves on the Educational Affairs Committee in the American College of Gastroenterology and has been elected to serve on the Clinical Practice Update Committee of American Gastroenterology Association.
Widely published with more 190 articles in peer-reviewed journals, Dr. Lee has written articles on topics, such as endoscopic ultrasound and fine-needle aspiration in unexplained bile duct strictures, pancreatic endosonography after Bilroth II gastrectomy, use of metallic biliary stents in unresectable pancreatic cancer, EUS and ERCP in one session. He has also lectured extensively at the national and international meetings, professional association meetings, academic forums, hospital Grand Rounds, and Live-Endoscopy courses. He was honored as Best Doctors in America from 2009-2018.

Dr. Lipika Goyal

Lipika Goyal, MD, MPhil is an Instructor of Medicine at Harvard Medical School and a member of the faculty in Gastrointestinal Medical Oncology at MGH Cancer Center. Her efforts focus on the development of effective therapies for hepatobiliary cancers through translational and clinical research. She receives support from the Cholangiocarcinoma Foundation, NIH/NCI GI SPORE, Executive Committee on Research at MGH, and the Kraft Foundation. She is the recipient of the CCF 2016 Andrea Marie Fuquay Research Fellowship.

Dr. Thomas Yau

MBBS (HK),MRCP (UK), FHKCP (Med Onc), FHKAM (Medicine)
Research Profile:
Treatment of Hepatobiliary Carcinoma
Treatment of Gastric and Colon cancer
Early Phase Clinical Trials
Translational Research in Cancers

Stacie Lindsey

Stacie is the cholangiocarcinoma foundation president. Stacie’s brother, Mark Clements, was diagnosed in 2005 and ultimately passed away from Cholangiocarcinoma on January 19, 2007. Stacie advocated for her brother, extensively researched treatment options and began networking with other patients, researchers and healthcare professionals. From this experience, the Cholangiocarcinoma Foundation was born. Stacie is a founding member and has served on the board of directors since its inception. Stacie resides in Salt Lake City, Utah, where she is the mother of five small children. She holds a Bachelor of Arts degree in Psychology from Brigham Young University, and is an active member in her church and community.

Patty Maxin

Patty is one of the cholangiocarcinoma foundation board memebrs. She received an M. Ed in Administration and Supervision from the University of Houston. She has dedicated her professional career focusing on the education of students with medical needs. In addition to her teaching responsibilities, she has a long history of involvement with various Houston charities and NGOs. In 2014, Ms Maxin retired from full time teaching in order to care for her husband, Mike Lu. He was diagnosed with cholangiocarcinoma the previous year. Following her husband’s death in 2015, she became involved with the Foundation. She is currently serving as the Program Manager for CholangioConnect.

Dr. Susan Acquisto

Susan Acquisto, DNP, R.N., NEA-BC, Chair, received her Doctor of Nursing Practice from University of San Francisco and is board certified in Nursing Administration. She is Co-Founder of The Bili Project Foundation based in California, that is dedicated to fund research for early detection, curative treatment options and improve the outcomes of Hepatobiliary cancers – cancers of the liver, gallbladder or bile ducts (Cholangiocarcinoma). She was the presenting author at the ASCO Palliative Care Conference in Boston in October 2015 on the Clinical Nursing Practice Guidelines for patients with Cholangiocarcinoma and is the recipient of the Association of California Nurse Leaders 2015 Best Practice- Excellence in Nursing Research ACNL award. She continues to work with the Nursing Advisory Board to publish these Guidelines in peer reviewed clinical journals to expand the knowledge of interdisciplinary clinical professionals in the care of these patients.